log in/ orientation introduction/ housekeeping
TRANSCRIPT
![Page 1: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/1.jpg)
Log in/ Orientation
Introduction/ Housekeeping
Dr Meg Cairns GP Liaison Officer
Metro North Health and Brisbane North PHN
![Page 2: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/2.jpg)
Time Task Presenter
8:00 am Log in/Orientation Dr Meg Cairns
8:15 am Housekeeping and Introductions Dr Meg Cairns
8:25 am Welcome Address Prof. Leonie Callaway
8:30 am Paediatric & Adolescent Gynaecology
Prof. Rebecca Kimble
9:00 am Cervical Screening Dr David Baartz9:30 am Termination of Pregnancy Dr Lindsay
Cochrane
Nicole Payne10:00 am Fertility Prof. Hayden
Homer10:30 am Menopause Hormone Therapy Prof. Hayden
Homer
Session 1
![Page 3: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/3.jpg)
Time Task Presenter
11:30 am Metro North Gynaecology Services and Referral Processes
Dr Meg Cairns
Gynaecology Nurse Unit Managers/ Care Coordinators
11:45 am Case Studies (Zoom Breakout Rooms)
All
1:30 pm Summary/Evaluation/Close Dr Meg Cairns
Session 2
![Page 4: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/4.jpg)
Acknowledgements
• Metro North Health
• Brisbane North PHN
• Caboolture Hospital, Redcliffe Hospital, Royal Brisbane & Women’s Hospital and The Prince Charles Hospital
• Metro North Health - Women’s and Children’s Stream - Metro North GP Alignment Program
• Metro North Health - Healthcare Excellence and Innovation - Outpatient and Primary Care Strategies
![Page 5: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/5.jpg)
Useful Resources
• MN HHS Gynaecology Referral Guidelines
https://metronorth.health.qld.gov.au/specialist_service/refer-your-patient/gynaecology
• GP Smart Referrals
https://brisbanenorthphn.org.au/practice-support/digital-health
• Brisbane North PHN eReferral templates
https://www.brisbanenorthphn.org.au/practice-support/referral-and-patient-management
![Page 6: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/6.jpg)
https://brisbanenorth.communityhealthpathways.org
HealthPathways
![Page 7: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/7.jpg)
https://brisbanenorth.communityhealthpathways.org
HealthPathways
![Page 8: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/8.jpg)
Brisbane North PHN – Network Link
![Page 9: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/9.jpg)
Health Provider Portal
• Secure online access to patients’ Queensland Health records:
https://hpp.health.qld.gov.au/
• Discharge summaries, SOPD appointments, medications, adverse reactions, pathology, medical imaging, procedures
• Patients can opt out - call 13HEALTH
![Page 10: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/10.jpg)
Useful Resources
• Australian Journal of General Practice
https://www1.racgp.org.au/ajgp/home
• RACGP gplearning and checkhttps://www.racgp.org.au/education/professional-development/online-learning
• RACGP Clinical guidelines
https://www.racgp.org.au/clinical-resources/clinical-guidelines
![Page 11: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/11.jpg)
Useful Resources
• RANZCOG statements and guidelines
https://ranzcog.edu.au/statements-guidelines
• RCOG The Initial Management of Chronic Pelvic Pain https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_41.pdf
• NICE guidelines
https://www.nice.org.uk/guidance/conditions-and-diseases/gynaecological-conditions
![Page 12: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/12.jpg)
Useful Resources
• Gynaecological Cancer https://www.health.gov.au/initiatives-and-programs/national-cervical-screening-program
https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening
https://www.canceraustralia.gov.au/cancer-types/gynaecological-cancers/clinicians-hub
![Page 13: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/13.jpg)
Useful Resources
• TRUE
https://www.true.org.au/course-catalogue
• Family Planning NSW
https://www.fpnsw.org.au/health-information/health-professionals
![Page 14: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/14.jpg)
Cervical ScreeningDr David Baartz, Senior Staff Specialist Gynaecology, Clinical Lead in Gynaecology and Director of the Qld Trophoblastic Centre
Royal Brisbane and Women’s Hospital
![Page 15: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/15.jpg)
Changes to the National Cervical Screening Program (NCSP) Guidelines for women at intermediate risk came into effect 1 February 2021
National Cervical Screening Program
![Page 16: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/16.jpg)
![Page 17: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/17.jpg)
https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening
![Page 18: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/18.jpg)
HPV (not-16/18) detected LBC negative, pLSIL or LSIL
Repeat HPV test in 12 months
12 month follow up HPV (not-16/18) detected LBC negative, pLSIL or LSIL
Repeat HPV test in a further 12 months’ time
![Page 19: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/19.jpg)
If HPV negative at second 12 month follow up
Return to 5 yearly screening
If HPV (any type) detected at second 12 month follow up, regardless of the result of reflex cytology
Refer for colposcopy
![Page 20: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/20.jpg)
• women 2 or more years overdue for screening at the time of the initial screen
• women who identify as Aboriginal or Torres Strait Islander
• women 50–69 yo• women with self-collected samples
If HPV (any type) is detected at 12 months, regardless of the result of reflex cytology, refer for
colposcopy
Exceptions
![Page 21: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/21.jpg)
Separate NCSP guidance for
• immune deficient women• women exposed to DES in utero• women currently undergoing Test of Cure
following treatment of histological HSIL• women aged > 70 yo attending for an exit test
Exceptions
![Page 22: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/22.jpg)
• Symptomatico Post-coital bleeding (>1 episode)o Unexplained intermenstrual bleedingo Post menopausal bleedingo Suspicious cervixo Persistent discharge or deep pelvic pain
• Test of Cure after treatment for HSIL (CIN2/3)• Previous endocervical adenocarcinoma in situ
(AIS) – annual Co-Test• Previous DES exposure – annual Co-Test
Indicate reason for Co-Test on pathology form
Co-Test Indications
![Page 23: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/23.jpg)
Endocervical cells are not required for specimen adequacy in a screening sample
Exception - at time of colposcopy, when the referral cytology was negative
What about endocervical cells ?
![Page 26: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/26.jpg)
![Page 27: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/27.jpg)
![Page 29: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/29.jpg)
Termination of PregnancyDr Lindsay Cochrane Director Obstetrics and Gynaecology, Caboolture Hospital
Nicole Payne
MNH Termination of Pregnancy Nurse Navigator
![Page 30: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/30.jpg)
Objectives:
•Understand key aspects of the 2018 Queensland
Termination of Pregnancy (ToP) Act
• Identify the role of a Conscientious Objector
• Identify Methods of Termination of Pregnancy
• Identify what to include in a Referral into Metro North
30
![Page 31: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/31.jpg)
31
ToP Act 2018
On 3 December, 2018
• Termination removed from the Criminal Code Act
1899
• The Termination of Pregnancy Act 2018 (ToP Act,
2018) became law
Purpose of the ToP Act:
• Enable reasonable and safe access by women to
termination
• Regulate the conduct of registered health
practitioners in relation to termination
![Page 32: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/32.jpg)
32
• Only a registered medical practitioner can perform a termination
• Specified registered health practitioners can assist a medical
practitioner
• It is a criminal offence if the person performing the termination is not
a registered health practitioner (as specified in the ToP Act)
• A woman does not commit an offence for termination on herself
Registered health practitioners who may assist a medical practitioner
with a termination include:
• Another medical practitioner
• Nurse, midwife, pharmacist
• Aboriginal and Torres Strait Islander health practitioner
• Others prescribed by law
Student health practitioners are not permitted under the ToP Act (2018)
to assist with a termination
ToP Act 2018
![Page 33: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/33.jpg)
33
What involvement can student health practitioners have in ToP?
Students can assist with:
• Clinical care before the
performance of the
termination (pre-operative
preparation, referral or
non-directive counselling)
• Intrapartum or postpartum
care after feticide or
administration of a
termination drug
Students cannot assist
with:
• Dispensing, supplying
or administering the
drug(s) to terminate
pregnancy
• Direct assistance with
surgical procedure for
termination of
pregnancy or feticide
![Page 34: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/34.jpg)
34
Less than 22 weeks gestation
At or more than 22+1 weeks gestation
A medical practitioner may perform a termination upon request
Two medical practitioners must consider all the circumstances and
both agree that a ToP should be performed
Circumstances that must be considered:
• Woman’s relevant medical, current and future physical,
psychological and social circumstances
• Professional standards and guidelines relevant to termination
![Page 35: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/35.jpg)
35
Health care professionals may
decline to provide ToP
healthcare on the basis of
conscientious objection
Conscientious objectors are
required
under the ToP Act 2018 to:
• Disclose their conscientious
objection to the woman
and/or other practitioners
who request assistance
• Refer care to another
practitioner who is not a
conscientious objector or to
another service
Conscientious Objection
I'm a conscientious
objector…
As a GP – What do
I need to do?
![Page 36: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/36.jpg)
36
Elly should:
• Immediately notify her line
manager of her
conscientious objection
• Discuss re allocation of
woman
• Provide support to other
staff in an emergency
situation
GPs who identify as conscientious objectors
must:
• Disclose to the patient their conscientious objection
• Refer care to another medical practitioner or service
who is not a conscientious objector
• Provide support to their patient including pregnancy
options counselling if appropriate and contraception
advice
• For women requesting M2Step – GP to GP referral is
recommended
![Page 37: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/37.jpg)
37
MS2-Step, Medical as Inpatient or Surgical Management?
MS2-Step
• Can be taken in
patients home if
assessed as suitable
• For women ≤9 weeks
gestation (63 days
gestation)
• Mifepristone/
Misoprostol
combination
• Must be a registered
prescriber with MS
Health
• Women should have
access to 24hr
emergency care if
required
• Follow up plan in
place
Medical ToP as
Inpatient
• Mifepristone/
misoprostol
combination
• Educated around
“what to expect”
• Feticide offered
after 22+1 weeks
gestation
• Memory Creation
• Legalities of birth at
given gestations
• Disposal of remains
/cremation/funeral
• Contraception can
be provided post
ToP prior to
discharge
Surgical ToP
• Up to 16 weeks
gestation in the public
health system – as per
service capability of
facility
• Consideration of use of
mifepristone pre Surgical
ToP
• Misoprostol for cervical
priming 2-3 hours pre op
• Usually day procedure
• Under general
anaesthetic
• POC respectfully
disposed of by hospital –
Women can request
private cremation
• LARC can be inserted at
the time of procedure
(e.g. Mirena or
Implanon)
![Page 38: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/38.jpg)
38
What to include in your referral
• Confirmed Viable Intrauterine
Pregnancy on Ultrasound – repeat
USS will be requested if viability not
confirmed
• Blood Group and Rh status, FBC,
quantitative B-HCG and current
cervical screening result
• STI screen
• BMI
• NIPT results (if attended)
• Other relevant investigations providing
evidence of fetal anomaly
![Page 40: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/40.jpg)
40
![Page 41: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/41.jpg)
41
![Page 42: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/42.jpg)
42
![Page 45: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/45.jpg)
Fertility
Professor Hayden HomerProfessor of Reproductive Medicine, University of Queensland Reproductive Endocrinology and Infertility Sub-specialist and Gynaecologist, Royal Brisbane and Women’s Hospital
![Page 46: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/46.jpg)
Infertility
• Affects 1:6 couples in Australia
• Inability to conceive after 12 months of unprotected SI
• 50% conceive after 6 months
• 80% after 12 months
• 90% after 18 months
![Page 47: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/47.jpg)
General considerations
• Couples should be seen together
• Welfare of the child
• Alcohol - nil
• Smoking - nil
• BMI : 19-30
• Folate : 0.5 mg per day
• Fitness for pregnancy
– Medical conditions
– Pre-conception counselling
![Page 48: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/48.jpg)
Fertility Factors
Eggs: Ovulation + Quality (Age) + Numbers (Ovarian Reserve)
Tubes: Patent and functional
Sperm: Concentration + Motility + Morphology
![Page 49: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/49.jpg)
What is the single most important determinant of pregnancy success?
FEMALE AGE
![Page 50: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/50.jpg)
Cornerstone of Reproduction
The oocyte provides nearly ALL membrane and cytoplasmic determinants including organelles and macromolecules required by the embryo
Li & Albertini 2013 Nature Reviews Molecular Cell Biology
![Page 51: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/51.jpg)
![Page 52: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/52.jpg)
0
10
20
30
40
50
60
70
26 28 30 32 34 36 38 40 42 44 46 48
Live
bir
th r
ate
(%
)
Maternal age (years)
Own eggs
Donor eggs
Oocyte quality is rate-limiting for pregnancysuccess
![Page 53: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/53.jpg)
0
10
20
30
40
50
60
70
26 28 30 32 34 36 38 40 42 44 46 48
Live
bir
th r
ate
(%
)
Maternal age (years)
Own eggs
Donor eggs
Oocyte quality is rate-limiting for pregnancy success
![Page 54: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/54.jpg)
4 cycles of IVF for under 35’s
80 cycles of IVF for over 45’s
Macaldowie et al. 2015. Assisted reproductive technology in Australia
and New Zealand 2013.
National Perinatal Epidemiology and Statistics Unit, UNSW.
Real-world impact of age-induced oocyte quality decline
![Page 55: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/55.jpg)
Ovulatory dysfunction: PCOS
• Affects 8-13% of women
• Estimated healthcare costs of up to $400M per year in Australia
• Accounts for 80% of anovulation
• Manifests three main groups of disorders:
– Hyperandrogenism (Effects of excess male hormones): hirsutism, acne and alopecia
– Infertility due to Anovulation
– Metabolic Disorders: Insulin resistance; Glucose Intolerance, Hyperlipidaemia etc.
![Page 56: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/56.jpg)
![Page 57: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/57.jpg)
PCOS diagnosis
Rotterdam criteria
2 out of the 3 of the following are required to make the diagnosis of PCOS:
1. Oligomenorrhoea or amenorrhoea
2. Clinical and/or biochemical evidence of hyperandrogenism
3. Polycystic ovaries - >20 follicles 2-8 mm in diameter or ovarian volume >10mls
![Page 58: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/58.jpg)
Managing PCOS: Focus on the individual problem
• PCO ovaries do not require treatment per se
• The term PCO is a misnomer
• “Cysts” are physiological follicles
• Weight loss for overweight patients is a very important
first line treatment regarding insulin resistance and
reducing risk of diabetes etc.
• Hyperandrogenism
• Fertility: Anovulation requires OI
![Page 59: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/59.jpg)
PCOS: Managing the endometrium
• Regular periods are not
mandatory or therapeutic
• Avoid amenorrhoea > 3
months to prevent
hyperplasia
• Progesterone to induce a
withdrawal bleed every 2-3
months e.g. Provera 10mg
daily for 7-10 days or
Prometrium 200mg daily for
12 days
![Page 60: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/60.jpg)
Case study – Mrs HC
32 G0P0 12/12 primary infertility
• Menstrual history
– Irregular menstrual cycle (average cycle length 3 months)
– Normal menstrual flow, mild dysmenorrhoea
• Past history
– BMI = 35
– No pelvic surgery or pelvic infection
![Page 61: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/61.jpg)
Case study: Mrs HC
• Investigation results:
– USS: PCO
– Partner’s SA - Normal
• Diagnosis:
– Anovulation secondary to
PCOS
![Page 62: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/62.jpg)
Fertility Factors
Eggs: Ovulation + Quality (Age) + Numbers (Ovarian Reserve)
Tubes: Patent and functional
Sperm: Concentration + Motility + Morphology
![Page 63: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/63.jpg)
Case study: Mrs HC - Treatment
• Weight loss: Diet and exercise
• Ovulation induction
– Letrozole – 2.5 mg D2-D6
– USS monitoring – 5-10% risk of multiple
pregnancy
– 3-6 ovulatory cycles
• Consider confirming tubal patency
– At the start
– If low risk, after 3 cycles if not pregnant
![Page 64: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/64.jpg)
Letrozole: Aromatase Inhibitor
![Page 65: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/65.jpg)
Tubal Factor
• Cause of infertility in up to 40% of women
• Main causes:
• Sexually transmitted infections (such as
chlamydia)
• Previous pelvic surgery (ruptured
appendix)
• Endometriosis
![Page 66: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/66.jpg)
Fallopian tube occlusion: HSG
![Page 67: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/67.jpg)
Case Study: Ms FT
28 G0P0 18/12 primary infertility
• Menstrual history
– Regular cycles /28
– Very painful
• Past history
– BMI = 23
– Previous chlamydia
![Page 68: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/68.jpg)
Case Study: Ms FT - HSG
Normal
Ms FT:
Bilateral
hydrosalpinges
![Page 69: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/69.jpg)
Case Study: Ms FT - Laparoscopy
Normal laparoscopy and dye Ms FT laparoscopy
![Page 70: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/70.jpg)
Case study: Ms FT - Treatment
• In vitro fertilization (IVF)
• Salpingectomy for hydrosalpinges
![Page 71: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/71.jpg)
IVF
In vitro fertilisation = fertilisation “in glass”
Egg fertilised by sperm outside of the body
![Page 72: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/72.jpg)
Overview of IVF
• Superovulation
• Cycle monitoring
• USS-guided Trans-
Vaginal
Egg Pick-up
• Fertilisation
• Standard
• ICSI
• Embryo culture
• Embryo transfer
![Page 73: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/73.jpg)
Case study: Mrs PM
• Female age = 39 years
• Narrow window of fertility left
• Do not wait for 12 months of
trying before referring
![Page 74: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/74.jpg)
Case study: Mrs PM
39; Primary infertility; TTC for 8 months
Menstrual history◦Regular cycles
Other history:◦BMI = 28◦No pelvic infection◦No prior surgery
Partner 45 ◦Smokes 20/day◦BMI 40
![Page 75: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/75.jpg)
Case study: Mrs PM
• Investigation results:
– Regular cycles Ovulating
– AMH = 2 pmol/L
– Partner’s SA
– Concentration = 10 M/ml
– Progressive motility = 20%
– Morphology = 1%
![Page 76: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/76.jpg)
AMH = 2 pmol/L
![Page 77: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/77.jpg)
Case study: Mrs PM
• Investigation results:
– Semen analysis (WHO 2010):
– Concentration > 15 M/ml
– Progressive motility 32%
– Morphology 4%
– Partner’s SA
– Concentration = 10 M/ml
– Progressive motility = 20%
– Morphology = 1%
![Page 78: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/78.jpg)
![Page 79: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/79.jpg)
Decline in sperm counts
Analysed samples from 42,935 men between 1973 and 2011
Overall decline in sperm counts of 50-60% in less than 40 years in North America, Europe, Australia and New Zealand
Levine et al. 2017 Human Reproduction Update
![Page 80: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/80.jpg)
Case study: Mrs PM - Treatment
• Diagnoses:
• Significant male factor
• Advanced female age with reduced
ovarian reserve
• Treatment:
– Weight loss and stop smoking
– IVF with ICSI
![Page 81: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/81.jpg)
Ovarian Reserve: AMH
• AMH is produced by the granulosa cells of growing preantral and small antral follicles up to 6-8 mm in diameter
• AMH levels correlate with NGF numbers assessed histologically
Hansen et al. 2011
• Do AMH levels predict natural fertility?
![Page 82: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/82.jpg)
AMH does NOT predict natural fertility
![Page 83: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/83.jpg)
Normal AMH Low AMH
Unlike IVF, natural fertility is dependent upon mono-ovulation
![Page 84: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/84.jpg)
Menopause Hormone Therapy
Professor Hayden HomerProfessor of Reproductive Medicine, University of Queensland Reproductive Endocrinology and Infertility Sub-specialist and Gynaecologist, Royal Brisbane and Women’s Hospital
![Page 85: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/85.jpg)
Overview
•Definition: Last menstrual period
•Postmenopausal: No periods for 12 months or more
•Average age of menopause: 51 years
•Early Menopause: Menopause between 40-45 years
•Premature Ovarian Insufficiency (POI): Menopause before 40 years
•Around one-third of women in Australia are above 50 years
![Page 86: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/86.jpg)
Diagnosis
Are special tests needed to make the diagnosis of menopause?
![Page 87: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/87.jpg)
Diagnosis
•Menopause is a normal physiological change brought about by depletion of ovarian follicles, which leads to oestrogen deficiency
•For women >45 years with menopausal symptoms, blood tests are NOT necessary or reliable
•During this time, hormone levels fluctuate widely and may include phases with normal and even high oestrogen levels
![Page 88: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/88.jpg)
Diagnosis of POI: ESHRE Guidelines 2016
•Oligo/amenorrhea for at least 4 months, and
•Elevated FSH level >25 IU/L on two occasions >4 weeks apart
![Page 89: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/89.jpg)
Symptoms
•Around 80% of menopausal women experience symptoms
•Symptoms typically persist for 4-8 years
•In 10-20% of women symptoms persist longer into their 60s and 70s
•Symptoms are due to lack of circulating oestrogen
![Page 90: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/90.jpg)
Symptoms
•Vasomotor symptoms: • Hot flushes and night sweats (60-80% of women)
•Skin and hair changes• Thinning, dryness, loss of elasticity and wrinkling of the skin • Sensation of “crawling” under the skin• Wrinkling is made worse by smoking and sun exposure
•Joints and bones: ◦ Aches and pains◦ Thinning of bone: 10% of bone mass is lost in first 5 years after
menopause◦ Around one-half of women >60 will have a fracture due to
osteoporosis
![Page 91: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/91.jpg)
Symptoms
•Weight distribution:• Altered weight distribution with fat accumulation in abdominal
region
•Disturbances in mood, memory and sleep• The occurrence of significant depressive symptoms doubles• 35-60% of women experience sleep problems
•Genitourinary syndrome of the menopause (GSM)• Vulvovaginal symptoms: Vaginal dryness • Sexual symptoms: Dyspareunia, reduced sex drive• Urinary symptoms: Dysuria, frequency, incontinence, prolapse
•Irregular bleeding
![Page 92: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/92.jpg)
Treatment: General measures
•Lifestyle changes:•Healthier eating habits
•Regular exercise
•Maintain healthy weight
•Avoid “triggers” for hot flushes:•Alcohol
•Spicy foods
•The most effective treatment is oestrogen therapy
![Page 93: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/93.jpg)
Menopausal Hormone Therapy (MHT)
• Formerly known as HRT
• MHT can be given as:• Oestrogen-only • Oestrogen + Progestogen (Combined MHT).
• Progestogens:• Prevent endometrial hyperplasia and are only needed in women
who have a uterus. • Women who have had a hysterectomy can use oestrogen on its
own and do NOT require progesterone.
![Page 94: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/94.jpg)
Menopausal Hormone Therapy (MHT)
• Oestrogens can be given as tablets, skin patches, gels, vaginal creams and vaginal pessaries.
• Progestogens:• More difficult to get into the body.• For MHT, can be given as tablets, patches or vaginal pessaries.
• Hormonal preparations with the same chemical structure as hormones found in the body are known as “body-identical”.
• “Bioidentical” is another term that is used, often to refer to compounded HT.
![Page 95: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/95.jpg)
Menopausal Hormone Therapy (MHT)
MHT is risky and should be avoided, right?
![Page 96: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/96.jpg)
Is MHT risky?
Australian clinicians reported that a woman’s fear of breast cancer was the main barrier to prescribing MHT Yeganeh et al. 2017 Climacteric
In Australia, 4% mortality from breast cancer and 31% from cardiovascular disease
![Page 97: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/97.jpg)
Women’s Health Initiative RCT Rossouw et al. 2002 JAMA
•Involved 27,347 women aged 50-79 years
•Mean age 63 years: much older than the peak age of 50-59 years for MHT use.
•Randomised to:•Combined MHT (CEE + MPA) or placebo (n=16,608) in women with an intact uterus
•CEE alone or placebo in hysterectomised women (n=10,739).
•Primary outcomes: Coronary heart disease and invasive breast cancer
![Page 98: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/98.jpg)
•Combined MHT study stopped after 5.2 years due to concerns regarding breast cancer (8-9 extra cases per 10,000 per year)
•No increased breast cancer in CEE-only group
•Subsequent analyses for women 50-59 or within 10 years of menopause: No increased breast cancer risk in either group
Manson et al. 2013 JAMA
Women’s Health Initiative RCT Rossouw et al. 2002 JAMA
![Page 99: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/99.jpg)
Women’s Health Initiative RCT
Combined MHT (CEE + MPA) in women aged 50-59 years
Manson et al. 2013 JAMA; Manson et al. 2017 JAMA
![Page 100: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/100.jpg)
Women’s Health Initiative Study
Conjugated equine oestrogen only in women aged 50-59 years
Manson et al. 2013 JAMA; Manson et al. 2017 JAMA
![Page 101: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/101.jpg)
MHT and breast cancer
• Oral combined MHT (CEE + MPA)• No increased risk if used for less than 5 years.
• Around 1 extra case per 1000 women if used >10 years.
• NO increased risk for oestrogen-only MHT
• Therefore, breast cancer risk linked to progesterone component
• Reduced risk with certain types of progestogens • Dydrogesterone
• Body-identical progesterone: Micronized progesterone (Prometrium)
![Page 102: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/102.jpg)
VTE and MHT Formulation
• Oral combined MHT (Data from WHI study)• Around 1 extra VTE per 1000 women if used >5 years in women
<60 years
• Recent very large study based on the UK primary care research database• ~80,000 women aged 40-79 with a first VTE and ~400,000
without VTE between 1998-2017• Formulation of combined MHT: • Highest increased risk (2.1 times) with CEE + MPA – very similar
to risk in the WHI study• Lowest increased risk (1.18 times) with oestradiol and
dydrogesterone• NO INCREASED RISK for transdermal oestrogen regardless of dose
(0.93 times increased risk)Vinogradova et al. 2019 BMJ
![Page 103: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/103.jpg)
Bone Health: General measures
•Calcium:• 1000-1300 mg per day is required and can be obtained from the diet. • Up to 60% of postmenopausal women do not meet dietary calcium
requirements.
•Vitamin D:• Required for calcium to be effectively used in bone formation. • Adequate levels can be derived from sufficient exposure to sunlight (5-15
minutes of exposure per day)• In Australia, 30-50% of postmenopausal women are deficient in vitamin D.
•Physical activity: • Weight-bearing exercise for 30-40 min on most days of the week such as
walking, jogging and dancing stimulate bone growth.
•Avoidance of smoking and reducing caffeine intake.
![Page 104: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/104.jpg)
Bone health: Strengthening and preventing loss
•Combined calcium and vitamin D supplements if diet inadequate.
•MHT:
• Should be started soon after the menopause for maximal benefit
• Can increase bone density by about 5% after 2 years
• Reduces the risk of spinal and hip fractures by ~40%.
•Tibolone: increases bone density and reduces fractures
•Raloxifene (SERM)
• Acts like oestrogen on bone leading to an increase in bone mass and reduced fractures.
• Does not stimulate the endometrium.
• Slight increased risk of DVT but no increased risk of breast cancer
• May block oestrogen effects at other sites and so may cause hot flushes.
![Page 105: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/105.jpg)
•Bisphosphonates: (e.g. Alendronate)
• Taken daily, weekly or monthly
• Reduce bone resorption
• Reduce bone loss and fractures
• Rare risk of osteonecrosis of the jaw
•Denosumab: reduces bone loss and fractures.
• 6 monthly injection
•Teriparatide:
• Bioactive fragment of parathyroid hormone.
• One 18-month course per lifetime
• Increases calcium absorption and bone formation.
• May need to be used in conjunction with calcium and vitamin D supplements.
Bone health: Strengthening and preventing loss
![Page 106: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/106.jpg)
Vulvovaginal Atrophy (GSM)
•Unlike vasomotor symptoms, VVA symptoms are often progressive
•On-demand non-hormonal vaginal moisturisers and lubricants
•Vaginal oestrogen is the preferred form of MHT and most effective treatment
•Two recent reports from large cohorts support safety of vaginal oestrogen
• WHI – 3000 women aged 50-79, 2 years’ usage
Crandall et al. 2018 Menopause
• Nurses’ Health Study – 900 women, 3 years’ usage Bhupathiraju et al. 2018 Menopause
• No increased risk for myocardial infarction, stroke, VTE, endometrial or breast cancer after 3 years of use
![Page 107: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/107.jpg)
Vulvovaginal Atrophy
•ACOG and North American Menopause Society recommend that low-dose vaginal oestrogen•Can be used indefinitely
•Progestogens NOT needed
American College of O&G Practice Bulletin No. 141. 2014 Obstet Gynecol
Position Statement of the North American Menopause Society. 2013 Menopause
•Treatment should be started early to prevent the development of distressing symptoms
![Page 108: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/108.jpg)
Vulvovaginal Atrophy
•Ospemifene: 3rd generation SERM•First-in-class with nearly full oestrogen agonist effect on the vaginal epithelium
•Oestrogen-agonist on bone
•Almost neutral estrogenic effects in the endometrium
•Reduces cell proliferation of ductal carcinoma in an in situmodel
![Page 109: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/109.jpg)
Vaginal laser use for VVA
•Lasers have not been cleared by the FDA for use specifically in VVA
•In July 2018, the FDA issued a consumer warning about CO2
laser therapy for vaginal cosmetic procedures or ‘vaginal rejuvenation’.
“These products have serious risks and don’t have adequate evidence to support their use for these purposes. We are deeply concerned women are being harmed.”
![Page 110: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/110.jpg)
Vaginal laser use for VVA
• First RCT involving vaginal laser for VVA Cruz et al. 2018 Menopause
• 45 women: • Laser + sham vaginal oestrogen • Vaginal oestrogen + sham laser • Laser + vaginal oestrogen (VE2)
• GSM scores most improved: laser+VE2 > VE2 > laser+shamVE2
• Worsened pain scores in laser only group• Very small study without a true sham-control arm
(sham laser+shamVE2) to adequately account for a placebo effect
![Page 111: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/111.jpg)
Vaginal laser use for VVA
•Reports of post-laser complications emerging Gordon et al. 2019 Menopause
•Two class-action lawsuits in US:
• One brought by patients
• One brought by healthcare professionals regarding marketing from laser companies
•Urgent need for large sham-controlled trials with long-term follow up capable of capturing all complications like fibrosis, scarring, agglutination and penetration injury
•US trial (VeLVET): At 6 months, vaginal laser and vaginal estrogen treatment resulted in similar improvement in genitourinary syndrome of menopause symptoms as well as urinary and sexual function. Overall, 70% to 80% of participants were satisfied or very satisfied with either treatment and there were no serious adverse events. Paraiso et al. 2020 Menopause
•Australian placebo-controlled RCT ongoing involving Mona Lisa laser
![Page 112: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/112.jpg)
Compounded “bioidentical” HT
•Use of systemic MHT has decreased by as much as 80% among U.S. women since the initial WHI publication in 2002
•Bioidentical hormones are marketed as “natural” on the basis of being derived from extracts such as yam and soybean BUT they are made from synthesized ingredients
•Unlike pharmaceutical grade MHT, compounded bioidentical hormones have not been rigorously evaluated in clinical trials
![Page 113: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/113.jpg)
Compounded “bioidentical” HT
•Used in the form of lozenges, troches and creams
•Survey of 3725 women in the US found that 35% of HT users were taking a compounded hormone
•Not regulated by the FDA
•Concerns about dose consistency, product contamination, and unsubstantiated safety and efficacy claims
•Australasian Menopause Society does NOT recommend the use of compounded bioidentical hormone therapy in any form
![Page 114: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/114.jpg)
Non-hormonal therapies: Vasomotor symptoms only
Nelson et al. 2006 JAMA; Position statement of the North American Menopause Society 2015 Menopause
![Page 115: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/115.jpg)
Nelson et al. 2006 JAMA; Position statement of the North American Menopause Society 2015 Menopause
Non-hormonal therapies: Vasomotor symptoms only
![Page 116: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/116.jpg)
Conclusions:
•Benefits outweigh risks for MHT in women 50-59 years or within the first 10 years of the menopause
•Transdermal routes are safer than oral routes and can be used in women with increased VTE risk or with BMI >30
•Vaginal oestrogen is a very safe and effective treatment for GSM
![Page 117: Log in/ Orientation Introduction/ Housekeeping](https://reader033.vdocuments.us/reader033/viewer/2022061503/629e98ca25866172420358bd/html5/thumbnails/117.jpg)
Conclusions:
•Body-identical hormones are the safest hormonal formulation
•Compounded bioidentical hormone therapy is not recommended
•MHT is not recommended for women with a history of hormone-dependent cancer
•More data are required on vaginal laser for treating GSM